Inflammatory bowel diseases (IBD) are a major health concern worldwide, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can cause harmful side effects.
A major reason successful IBD therapies remain elusive is because current model systems cannot replicate key mechanistic aspects of the epithelial inflammatory response in humans.
That's why we developed InflammaScreen™ Services, a suite of pre-qualified, multiple readout assays using our flagship model RepliGut® Planar Transverse Colon. These assays are specifically designed to both speed up discovery and improve the human relevance of gastrointestinal inflammation focused drug discovery.
Ways to benefit from an InflammaScreen Study
Triage larger chemical sets to identify most promising candidates
Compare candidates to gain clarity on overlapping or discerning functionalities
Achieve fast iterative turnaround while optimizing structure and function
Save money and time by eliminating ineffective molecules early
Results from InflammaScreen™ Services will give you clinically relevant insights into how your test drugs will interact with the inflamed intestinal epithelium using a standard format with rapid turnaround times